Results 21 to 30 of about 1,279,721 (336)

Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection

open access: yesScientific Reports, 2023
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of BC but this remains largely ...
L. Baxter   +14 more
doaj   +1 more source

Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019

open access: yesMilitary Medical Research, 2021
Background The burden of kidney, bladder, and prostate cancers has changed in recent decades. This study aims to investigate the global and regional burden of, and attributable risk factors for genitourinary cancers during the past 30 years.
Hao Zi   +15 more
semanticscholar   +1 more source

Diabetes-induced alterations in urothelium function:Enhanced ATP release and nerve-evoked contractions in the streptozotocin rat bladder [PDF]

open access: yes, 2018
Up to 80% of patients with diabetes mellitus develop lower urinary tract complications, most commonly diabetic bladder dysfunction (DBD). The aim of this study was to investigate the impact of diabetes on the function of the inner bladder lining ...
Apodaca   +56 more
core   +1 more source

Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center [PDF]

open access: yes, 2019
Objectives: To evaluate accuracy and inter-observer variability using Vesical Imaging-Reporting and Data System (VI-RADS) for discrimination between non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
Barchetti, Giovanni   +11 more
core   +1 more source

Epidemiology of Bladder Cancer

open access: yesMedical Science, 2020
Based on the latest GLOBOCAN data, bladder cancer accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. In the United States, bladder cancer is the sixth most incident neoplasm.
Kalyan Saginala   +5 more
semanticscholar   +1 more source

Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m6A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer

open access: yesCancer Research, 2021
A newly characterized circRNA circ0008399 binds WTAP to modulate expression of target RNA through m6A modification and reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Wenjie Wei   +9 more
semanticscholar   +1 more source

Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]

open access: yes, 2017
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K   +7 more
core   +2 more sources

A prospective observational study of urinary cytokines and inflammatory response in patients with Overactive Bladder Syndrome

open access: yesBMC Urology, 2021
Background Contemporary studies have discredited the methods used to exclude urinary tract infection (UTI) when treating overactive bladder (OAB). Thus we must revisit the OAB phenotype to check that UTI has not been overlooked.
Kiren Gill   +4 more
doaj   +1 more source

Bowel dysfunction after transposition of intestinal segments into the urinary tract : 8-year prospective cohort study [PDF]

open access: yes, 2007
Purpose Bowel function may be disturbed after intestinal segments are transposed into the urinary tract to reconstruct or replace the bladder. In 1997, our group were the first to report major bowel dysfunction in a cohort of such patients: up to 42% of ...
ABACUS Research Group   +8 more
core   +1 more source

Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast

open access: yesOncology and Therapy, 2023
In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional.
Alex Filicevas, Thomas Powles
doaj   +1 more source

Home - About - Disclaimer - Privacy